Research location
Brighton
Sussex, United Kingdom
Advertisement
Research activity in Brighton
Sussex, United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 12 trials and 12 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Brighton
12 linked trials · page 1 of 1Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom.NCT05188144 · 2021-11-29 · 1 site observation
COMPLETED
Mindfulness-Based Cognitive Therapy for Depressed IAPT Non-RespondersNCT05236959 · 2021-01-01 · 1 site observation
UNKNOWN
Trans People Living With HIV Throughout EuropeNCT03922269 · 2019-10-11 · 1 site observation
COMPLETED
Study of Mirtazapine for Agitation in DementiaNCT03031184 · 2017-01-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerNCT02007512 · 2013-12-16 · 1 site observation
COMPLETED
The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'NCT01737047 · 2013-04-01 · 1 site observation
COMPLETED
MARCH Central Nervous System SubstudyNCT01637233 · 2012-06-01 · 1 site observation
COMPLETED
MARCH Renal SubstudyNCT01637259 · 2012-06-01 · 1 site observation
COMPLETED
Maraviroc Switch Collaborative StudyNCT01384682 · 2011-08-01 · 1 site observation
COMPLETED
Pre-Exposure Prophylaxis Using TMC278LANCT01049932 · 2010-03-01 · 1 site observation
TERMINATED
Expanded Access Program for Maraviroc At Multiple CentersNCT00426660 · 2007-02-01 · 1 site observation
COMPLETED
Warfarin and Antiplatelet Therapy in Chronic Heart FailureNCT00007683 · 1998-10-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.